|Systematic (IUPAC) name|
|Mol. mass||313.44 g/mol|
|(what is this?)|
Oxilorphan has some weak partial agonist effects and can produce hallucinogenic/dissociative effects at high doses, suggesting some kappa opioid agonist action. It was trialled for the treatment of opiate addiction, but was not developed commercially. Oxilorphan's mu-opioid antagonist and kappa-opioid agonist effects are associated with dysphoria, which combined with the hallucinogenic properties of kappa-opioid agonism limit the clinical usefulness of the drug.
- Pircio AW, Gylys JA. Oxilorphan (l-N-cyclopropylmethyl-3,14-dihydroxymorphinan): a new synthetic narcotic antagonist. Journal of Pharmacology and Experimental Therapeutics. 1975 Apr;193(1):23-34.
- Sellers EM, Thakur R. Partial agonist properties and toxicity of oral oxilorphan. Journal of Clinical Pharmacology. 1976 Apr;16(4):183-7.
- Leander JD. Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a kappa-opioid receptor. European Journal of Pharmacology. 1983 Jan 21;86(3-4):467-70.
- Tennant FS Jr, Tate JA, Ruckel E. Clinical trial in post-addicts with oxilorphan (levo-BC-2605): a new narcotic antagonist. Drug and Alcohol Dependence. 1976 Jun;1(5):329-37.